🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2 Low Breast Carcinoma

Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer NCT07844473NA1 site📍 Madinah King Faisal Specialist Hospital & Research Center · Tests: Super paramagnetic iron oxide bracketing injection Validation of the Oncoliq Test for the Early Detection of Breast Cancer. NCT07331506n/a1 site📍 Buenos Aires Oncoliq US Inc · Tests: Peripheral blood draw SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230Phase 21 site📍 Shenyang Shengjing Hospital · Tests: SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection IKS014 in Advanced Solid Tumors That Express HER2 NCT05872295Phase 113 sites📍 Newport Beach📍 Boston📍 Nashville Iksuda Therapeutics Ltd. · Tests: IKS014 Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer NCT06706557n/a1 site📍 Milan European Institute of Oncology A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, DS-8201 Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945Phase 388 sites📍 Miami Beach📍 Tampa📍 Boston Daiichi Sankyo · Tests: Trastuzumab Deruxtecan Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients NCT06722599n/a1 site📍 Beijing Shu Wang DESTINY Breast Respond HER2-(Ultra)Low Europe NCT05945732n/a216 sites📍 Graz📍 Graz📍 Innsbruck Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Tests: Trastuzumab deruxtecan PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan NCT05573893n/a109 sites📍 Amberg📍 Ansbach📍 Apolda AstraZeneca Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites📍 Aviano📍 Brescia📍 Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Palbociclib, Ribociclib, Abemaciclib Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer NCT06877416n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: Non-intervention research Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635Phase 217 sites📍 Santa Monica📍 Skokie📍 Billings Merck Sharp & Dohme LLC · Tests: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites📍 Scottsdale📍 Los Angeles📍 Palo Alto Cogent Biosciences, Inc. · Tests: CGT6297 Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer NCT07117864NA1 site📍 Beijing QIAO LI · Tests: T-DXd concurrent brain radiotherapy TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd NCT06533826Phase 211 sites📍 Birmingham📍 San Francisco📍 New Haven Ana C Garrido-Castro, MD · Tests: Trastuzumab Deruxtecan, Datopotamab Deruxtecan Gene Therapy for HER-Positive Cancer (SENTRY-HER2) NCT07192432Phase 1, Phase 211 sites📍 Los Angeles📍 Denver📍 Jacksonville Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202 To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer NCT06389006Phase 21 site📍 Shanghai RemeGen Co., Ltd. · Tests: Disitamab Vedotin for Injection, Toripalimab, Epirubicin, Cyclophosphamide OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk NCT05333328Phase 42 sites📍 Seoul📍 Seoul Gangnam Severance Hospital · Tests: Ovarian function suppression with endocrine treatments Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial NCT06176534Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: Experimental: chemotheyapy, Active Comparator: endocrine therapy Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer NCT04553770Phase 29 sites📍 Fullerton📍 Los Alamitos📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS NCT05792150n/a71 sites📍 Baden-Baden📍 Pforzheim📍 Stuttgart Women's Cancer Study Group GmbH A Study of Skipping Radiation Therapy in People With Breast Cancer NCT07895511NA7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: HER2-targeted therapy, Tamoxifen, No Radiation Therapy Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer NCT07630402NA1 site📍 Rochester University of Rochester · Tests: Echocardiogram A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC NCT06439771Phase 21 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202 should be intravenously infused Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors NCT07287917Phase 1, Phase 220 sites📍 Tucson📍 La Jolla📍 Los Angeles Aminex Therapeutics, Inc. · Tests: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial NCT07391774Phase 3226 sites📍 Jonesboro📍 Auburn📍 Berkeley National Cancer Institute (NCI) · Tests: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk NCT05297617Phase 22 sites📍 Limoges📍 Villejuif UNICANCER · Tests: Anti-aromatase inhibitor Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer NCT07817082Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: SHR- A1811 Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy NCT06953882Phase 21 site📍 New Haven Yale University · Tests: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy